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Abstract
Multi-omics datasets can provide molecular insights beyond the
sum of individual omics. Various tools have been recently devel-
oped to integrate such datasets, but there are limited strategies to
systematically extract mechanistic hypotheses from them. Here,
we present COSMOS (Causal Oriented Search of Multi-Omics
Space), a method that integrates phosphoproteomics, transcrip-
tomics, and metabolomics datasets. COSMOS combines extensive
prior knowledge of signaling, metabolic, and gene regulatory
networks with computational methods to estimate activities of
transcription factors and kinases as well as network-level causal
reasoning. COSMOS provides mechanistic hypotheses for experi-
mental observations across multi-omics datasets. We applied
COSMOS to a dataset comprising transcriptomics, phosphopro-
teomics, and metabolomics data from healthy and cancerous
tissue from eleven clear cell renal cell carcinoma (ccRCC) patients.
COSMOS was able to capture relevant crosstalks within and
between multiple omics layers, such as known ccRCC drug targets.
We expect that our freely available method will be broadly useful
to extract mechanistic insights from multi-omics studies.
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Introduction
“Omics” technologies measure at the same time thousands of mole-
cules in biological samples, from DNA, RNA, and proteins to
metabolites. Omics datasets are an essential component of systems
biology and are made possible by the popularization of analytical
methods such as next-generation sequencing or mass spectrometry.
Omics data have enabled the unbiased characterization of the
molecular features of multiple human diseases, particularly in
cancer (preprint: Jelinek & Wu, 2012; Iorio et al, 2016; Subramanian
et al, 2017). It is becoming increasingly common to characterize
multiple omics layers in parallel, with so-called “trans-omics analy-
sis”, to gain biological insights spanning multiple types of cellular
processes (Sciacovelli et al, 2016; Kawata et al, 2018; Vitrinel et al,
2019). Consequently, many tools are developed to analyze such
data (Tenenhaus et al, 2014; Argelaguet et al, 2018; Sharifi-Noghabi
et al, 2019; Singh et al, 2019; Liu et al, 2019c), mainly by adapting
and combining existing “single omics” methodologies to multiple
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parallel datasets. These methods identify groups of measurements
and derive integrated statistics to describe them, effectively reducing
the dimensionality of the datasets. These methods are useful to
provide a global view of the data, but additional processing is
required to extract mechanistic insights from them.
To extract mechanistic insights from datasets, some methods
(such as pathway enrichment analysis) use prior knowledge about
the players of the process being investigated. For instance, differen-
tial changes in the expression of the genes that constitute a pathway
can be used to infer the activity of that pathway. Methods that a
priori define groups of measurements based on known regulated
targets (that we call footprints (Dugourd & Saez-Rodriguez, 2019))
of transcription factors (TFs; Alvarez et al, 2016; Garcia-Alonso
et al, 2019), kinases/phosphatases (Wiredja et al, 2017), and path-
way perturbations (Schubert et al, 2018) provide integrated statistics
that can be interpreted as a proxy of the activity of a molecule or
process. These methods seem to estimate more accurately the status
of processes than classic pathway methods (Cantini et al, 2018;
Schubert et al, 2018; Dugourd & Saez-Rodriguez, 2019). Since each
of these types of footprint methods works with a certain type of
omics data, finding links between them could help to interpret them
collectively in a mechanistic manner. For example, one can use a
network diffusion algorithm, such as TieDIE (Paull et al, 2013), to
connect different omics footprints together (Drake et al, 2016). This
approach provides valuable insights, but diffusion (or random walk)
based algorithms do not typically take into account causal informa-
tion (such as activation/inhibition) that is available and are essen-
tial to extract mechanistic information. TieDIE partially addressed
this problem by focusing the diffusion process on causally coherent
subparts of a network of interest, but it is thus limited to local
causality.
Recently, we proposed the CARNIVAL tool (Liu et al, 2019b) to
systematically generate mechanistic hypotheses connecting TFs
through global causal reasoning supported by Integer Linear
Programming. CARNIVAL connects activity perturbed nodes such as
drug targets with deregulated TFs activities by contextualizing a
signed and directed Prior Knowledge Network (PKN). We had
hypothesized how such a method could potentially be used to
connect footprint-based activity estimates across multiple omics
layers (Dugourd & Saez-Rodriguez, 2019).
In this study, we introduce COSMOS (Causal Oriented Search of
Multi-Omics Space). This approach connects TF and kinase/phos-
phatases activities (estimated with footprint-based methods) as well
as metabolite abundances with a novel PKN spanning across multi-
ple omics layers (Fig 1). COSMOS uses CARNIVAL’s Integer Linear
Programming (ILP) optimization strategy to find the smallest coher-
ent subnetwork causally connecting as many deregulated TFs,
kinases/phosphatases, and metabolites as possible. The subnetwork
is extracted from a novel integrated PKN spanning signaling, tran-
scriptional regulation, and metabolism of > 117,000 edges. CARNI-
VAL’s ILP formulation effectively allows to evaluate the global
network’s causal coherence given a set of known TF, kinases/phos-
phatases activities and metabolite abundances. While we showcase
this method using transcriptomics, phosphoproteomics, and meta-
bolomics inputs, COSMOS can theoretically be used with any other
additional inputs, as long as they can be linked to functional
insights (for example, a set of deleterious mutations). As a case
study, we generated transcriptomics, phosphoproteomics, and
metabolomics datasets from kidney tumor tissue and corresponding
healthy tissue out of nine clear cell renal cell carcinoma (ccRCC)
patients. We estimated changes of activities of TFs and kinase/phos-
phatases as well as metabolite abundance differences between
tumor and healthy tissue. We integrated multiple curated resources
of interactions between proteins, transcripts, and metabolites
together to build a meta PKN. Next, we contextualized the meta
PKN to a specific experiment. To do so, we identified causal path-
ways from our prior knowledge that connect the observed changes
in activities of TFs, kinases, phosphatases, and metabolite abun-
dances between tumor and healthy tissue. These causal pathways
can be used as hypothesis generation tools to better understand the
molecular phenotype of kidney cancer. We also refactored all func-
tions to run the COSMOS approach into an R package.
Results
Building the multi-omics dataset
To build a multi-omics dataset of renal cancer, we performed tran-
scriptomics, phosphoproteomics, and metabolomics analyses of
renal nephrectomies and adjacent normal tissues of 11 renal cancer
patients (for details on the patients see Dataset EV1). First, we
processed the different omics datasets to prepare for the analysis.
For the transcriptomics dataset, 15,919 transcripts with average
counts > 50 were kept for subsequent analysis. In the phosphopro-
teomics dataset, 14,243 phosphosites detected in at least four
samples were kept. In the metabolomics dataset, 107 metabolites
detected across 16 samples were kept. Principal component analysis
(PCA) of each omics dataset independently showed a clear separa-
tion of healthy and tumor tissues on the first component (transcrip-
tomics: 40% of explained variance (EV), phosphoproteomics: 26%
of EV, metabolomics: 28% of EV, Fig EV1), suggesting that tumor
sample displayed molecular deregulations spanning across signal-
ing, transcription and metabolism. Each omics dataset was indepen-
dently submitted to differential (tumor vs. healthy tissue) analysis
using LIMMA (Ritchie et al, 2015). Consistently with the PCA, a
volcano plot overlapping the results of the differential analysis of
each omics showed that the transcriptomics dataset led to larger dif-
ferences and smaller P-values than phosphoproteomics and metabo-
lomics extracted from the same samples (Fig EV2). This is further
apparent by the number of hits under a given false discovery rate
(FDR, Benjamini & Hochberg, 1995) threshold. We obtained 6,699
transcripts and 21 metabolites significantly regulated with
FDR < 0.05. While only 11 phosphosites were found under 0.05
FDR, 447 phosphosites had an FDR < 0.2. This result confirmed the
deep molecular deregulations of tumors spanning across signaling,
transcription, and metabolism. Then, the differential statistics for all
tested (not just the ones under the FDR threshold) transcripts, phos-
phopeptides, and metabolites were used for further downstream
analysis, as explained below.
Footprint-based transcription factor, kinase, and phosphatase
activity estimation
We then performed computational footprint analysis to estimate the
activity of proteins responsible for changes observed in specific
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omics datasets. By the term “activity”, we refer to a quantifiable
proxy of the function of a protein, estimated based on the footprint
left by said activity. This definition can apply, but is not limited to,
an enzyme’s catalytic activity. Footprint-based activity estimation
(Dugourd & Saez-Rodriguez, 2019) relies on the concept that the
measured abundances of molecules (such as phosphopeptides or
transcripts) can be used as a proxy of upstream (direct or indirect)
regulator activities responsible for those changes (Rhodes et al,
2005; Casado et al, 2013; Ochoa et al, 2016). In the case of TF activ-
ity estimation, this means that measured changes in the abundances
of transcripts give us information about the changes of activities of
the transcription factors that regulate their abundance. An activity
estimation only depends on the changes of the abundances
measured in its target transcripts, not its own transcript abundance.
In this study, we used the VIPER algorithm (Alvarez et al, 2016) to
estimate the activity of transcription factors and kinases based on
transcript and phosphopeptide abundances changes, respectively.
For transcriptomics and phosphoproteomics data, this analysis esti-
mates transcription factor and kinases/phosphatase activity, respec-
tively. 24,347 transcription factors (TFs) to target interactions (i.e.,
transcript under the direct regulation of a transcription factor) were
obtained from DoRothEA (Garcia-Alonso et al, 2019), a meta-
resource of TF-target interactions. Those TF-target interactions span
over 365 unique transcription factors. In parallel, 33,616 interac-
tions of kinase/phosphosphate and their phosphosite targets (i.e.,
phosphopeptides directly (de)phosphorylated by specific kinases
(phosphatases)) were obtained from OmniPath (T€urei et al, 2016)
kinase substrate network, a meta-resource focused on curated infor-
mation on signaling processes. Only TFs and kinases/phosphatases
with at least 10 and 5 detected substrates, respectively, were
included. This led to the activity estimation of 328 TFs and 174
kinases. In line with the results of the differential analysis, where
fewer phosphosites were deregulated than transcripts, TF activities
displayed a stronger deregulation than kinases. TF activity scores
reached a maximum of 8.7 standard deviations (sd) for Transcrip-
tion Factor Spi-1 Proto-Oncogene (SPI1) (compared to the null score
distribution; sd compared to null is also referred to as a normalized
enrichment score, NES), while kinase activity scores reached a
maximum of 4.6 NES for Casein Kinase 2 Alpha 1 (CSNK2A1). In
total, 102 TFs and kinases/phosphatase had an absolute score over
1.7 NES (P < 0.05) and were considered significantly deregulated in
kidney tumor samples (Fig 2A). The presence of several known
signatures of ccRCC corroborated the validity of our analysis. For
instance, hypoxia (HIF1A), inflammation (STAT2, Fig 2B), and
oncogenic (MYC, Cyclin Dependent Kinase 2 and 7 (CDK2/7,
(Fig 2C)) markers were up-regulated in tumors compared to healthy
tissues (Zeng et al, 2014; Sch€odel et al, 2016; Clark et al, 2020).
Furthermore, among suppressed TFs we identified, the HNF4A gene
has been previously associated with ccRCC (Lucas et al, 2005).
Causal network analysis
We set out to find potential causal mechanistic pathways that could
explain the changes we observed in TF, kinases/phosphatase activi-
ties, and metabolic abundances. Thus, we developed a systematic
approach to search in public databases, such as OmniPath, for plau-
sible causal links between significantly deregulated TFs, kinases/
phosphatases and metabolites. In brief, we investigated if changes in
TF, kinase/phosphatase activities, and metabolite abundance can
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Figure 1. Overview of analysis pipeline.
From left to right: We sampled and processed 11 patient tumors and healthy kidney tissues from the same kidney through RNA-sequencing and 9 of those same
patients through mass spectrometry to characterize their transcriptomics, phosphoproteomics, and metabolomics profiles. We calculated differential abundance for each
detected gene, phosphopeptide, and metabolite. We estimated kinase and transcription factor activities using the differential analysis statistics and footprint-based
methods. We used the estimated activities alongside the differential metabolite abundances to contextualize (i.e., extract the subnetwork that better explains the
phenotype of interest) a generic trans-omics causal prior knowledge network (meta PKN).
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interactions. An example of such a mechanism can be the activation
of the transcription of MYC gene by NFKB1. Since both NFKB1 and
MYC display increased activities in tumors, and there is evidence in
the literature that NFKB1 can regulate MYC transcription (FANTOM4
database), it may indicate that this mechanism is responsible for this
observation.
First, we needed to map the deregulated TFs, kinases, and
metabolites on a causal prior knowledge network spanning over
signaling pathways, gene regulation, and metabolic networks.
Hence, we combined multiple sources of experimentally curated
causal links together to build a meta causal prior knowledge
network. This meta PKN must include direct causal links between
proteins (kinase to kinase, TF to kinase, TF to metabolic enzymes,
etc. . .), between proteins and metabolites (reactants to metabolic
enzymes and metabolic enzymes to products) and between metabo-
lites and proteins (allosteric regulations). High confidence (≥ 900
combined score) allosteric regulations of the STITCH database (Szk-
larczyk et al, 2016) were used as the source of causal links between
metabolites and enzymes (Fig 3A). The directed signed interactions
of the OmniPath database were used as a source of causal links
between proteins (Fig 3B). The human metabolic network Recon3D
(Brunk et al, 2018) (without cofactors and hyper-promiscuous
metabolites, see Material and Methods) was converted to a causal
network and used as the source of causal links between metabolites
and metabolic enzymes (Fig 3C). The resulting meta PKN consists of
117,065 interactions and contains causal paths linking TFs/kinases/
phosphatases with metabolites and vice versa in a machine readable
format. This network is available in the COSMOS R package.
We then used the meta PKN to systematically search causal paths
between the deregulated TFs, kinases/phosphatases, and metabo-
lites using an ILP optimization approach (see Material and Methods,
















































































































































































Figure 2. Differentially regulated transcription factor, kinase, and phosphatase activities cancer vs. healthy tissue.
A Bar plot displaying the normalized enrichment score (NES, proxy of activity change) of the 25 up- or down-regulated TF and top 25 up- or down-regulated kinase and
phosphatases activities between kidney tumor and adjacent healthy tissue.
B Right panel shows the 10 most changing RNA abundances of the STAT2 regulated transcripts . Left panel shows the change of abundances of all STAT2 regulated
transcripts that were used to estimate its activity change. X-axis represents log fold change of regulated transcripts multiplied by the sign of regulation (1 for
inhibition and 1 for activation of transcription). Y-axis represents the significance of the log fold change (log10 of P-value, LIMMA moderated unpaired t-test P-
values). The black line is defined by the following function when fold change is negative : y = abs(hAss  1 + x/(x + vAss)); and y = abs(hAss  1 + x/(x  vAss))
when fold change is positive. abs() is the absolute value, hAss is the horizontal asymptote (hAss = 1.3) and vAss is the vertical asymptote (vAss = 0.3).
C Right panel shows the 10 most changing phosphopeptide abundances of the CDK7 regulated phosphopeptides. Left panel shows the change of abundances of all
CDK7 regulated phosphopeptides that were used to estimate its activity change. X-axis represents log fold change of regulated transcripts multiplied by the sign of
regulation (1 for inhibition and 1 for activation of transcription). Y-axis represents the significance of the log fold change (log10 of P-value, LIMMA moderated
unpaired t-test P-values). The black line is defined by the following function when fold change is negative : y = abs(hAss  1 + x/(x + vAss)); and y = abs
(hAss  1 + x/(x  vAss)) when fold change is positive. Where abs() is the absolute value, hAss is the horizontal asymptote (hAss = 1.3) and vAss is the vertical
asymptote (vAss = 0.3).
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meta PKN to find the smallest sign-coherent subnetwork connecting
as many deregulated TFs, kinases/phosphatases, and metabolites as
possible. First, we filtered out all interactions that do not involve
genes expressed in our samples. Then, we removed nodes beyond a
given number of steps downstream of inputs. We also removed any
edge that leads to an incoherence between a TF activity score and
the transcript abundance change of its targets (Appendix Fig S1A).
We then performed a CARNIVAL run from TFs/kinases/phos-
phatases to metabolites to estimate the activity of TFs in the
COSMOS solution network. These activities are used to filter out
incoherent transcriptional regulation events from the meta PKN.
Then, CARNIVAL is used to find causal paths going from TFs/ki-
nases/phosphatases to the metabolites (the “forward network”).
Finally, CARNIVAL is used to go from metabolites to TFs/Kinases/
phosphatases (“backward network”). The choice of TFs/Kinases/
phosphatases and metabolites to be included is detailed in
Appendix Note 1. We combined the two networks (making union of
the two sets edges and the union of the two sets of node attributes)
to obtain a network with 449 unique edges (Appendix Fig S2,
Dataset EV5). CARNIVAL finds a direct path connecting down-
stream measurements with upstream nodes, and thus, the solution
networks do not contain loops. Loops can however appear in the
final merged network when nodes are overlapping between
“forward” and “backward” runs.
We then used our network to investigate the regulation of rele-
vant signaling cascades and metabolic reactions in ccRCC. An over-
representation analysis of the network solution nodes (with the hall-
mark genesets of MSigDB) displayed the interferon gamma (IFNg)
response as the top significant pathway in our COSMOS network.
Hence, we focused on the interaction members of this pathway
(such as NFKB1, HIF1A, and PNP) and their crosstalks with meta-
bolic deregulations to assess the relevance of the mechanistic
hypotheses generated by COSMOS. We found that NFKB1, a central
actor of the IFNg pathway is activated in ccRCC, consistently with
other reports (Zhang et al, 2018; Rodrigues et al, 2018) where it was
also demonstrated to be regulated by the PI3K/AKT pathway (An &
Rettig, 2007). Interestingly, COSMOS also proposed the activation of
BCAT1, one of the key enzymes of the branched-chain amino acid
metabolism, orchestrated by HIF1A and MYC (Gordan et al, 2008;
Ananieva & Wilkinson, 2018). Both mechanisms are shown in Fig 4
(1) and (2).
Of note, COSMOS provided deeper insights into these molecular
mechanisms by linking MYC activation to NFKB1. The COSMOS
model suggests that MYC up-regulates the expression of the meta-
bolic enzyme BCAT1, potentially leading to the observed higher
levels of glutamate, glutamine and reduced glutathione in ccRCC
(marked as (2) in Fig 4). A strong role of MYC and glutamine meta-





























Figure 3. Graphical explanation of meta PKN sources.
A–C Schematic representation of the meta generic network (meta PKN) created combining STITCH, OmniPath and Recon3D. (A) STITCH provides information on
inhibition/activation of enzyme activities mediated by metabolites. (B) OmniPath provides information inhibition/activation of enzyme activities mediated by other
enzymes based mainly on curated resources. (C) Recon3D provides information on reactants and products associated with metabolic enzymes. To make this
information compatible with the causal edges from OmniPath and STITCH, the interactions of recon3D are converted so that reactants “activate” their metabolic
enzymes, which themselves “activate” their products.
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Consistently with what was hypothesized in a recent proteoge-
nomics ccRCC study (Clark et al, 2020), we were able to capture
crosstalks between members of the interferon gamma pathway
(such as JUN), YY1 and metabolic down-regulation observed in our
data ((3) in Fig 4). COSMOS highlighted how YY1 inhibition might
be connected with the depletion of adenine, hypoxanthine, and
inosine through regulation of the ADA and PNP metabolic enzyme
(Popławski et al, 2017). The low levels of adenosine predicted by
COSMOS might also be potentially linked to the down-regulation of
AKT3 and up-regulation of YES1, through a cascade which involves
both ADORA2B and GNAI1, downstream of s-Adenosyl-L-homocys-
teine and inhibition of KMT2A ((4) in Fig 4). Finally, the COSMOS
model showed a significant activation of MAPK1 and SMAD4 down-
stream of YES1 (a member of the SRC family) ((5) in Fig 4).
Consistency, robustness, and flexibility
Due to the combined effect of experimental noise and incomplete-
ness of prior knowledge (kinase/substrate interactions, TF/targets
interactions and meta PKN), it is critical to assess the performance
of the pipeline presented above.
One way to estimate the performance is to check if the COSMOS
mechanistic hypotheses correspond to correlations observed in
tumor tissues (Appendix Fig S1B). Thus, on the one hand, a topol-
ogy-driven co-regulation network was generated from the COSMOS
network. The assumption behind this network is that direct down-
stream targets of the same enzymes should be co-regulated. On the
other hand, a data-driven correlation network of TFs, kinases, and
phosphatases was generated from tumor tissues alone. Assuming
thresholds of absolute values of correlation ranging between 0 and 1
to define true positive co-regulations, the comparison between the
topology-driven co-regulation network and the data-driven correla-
tion network yielded a TPR ranging between 0.55 and 0 (n = 269
pairs of predicted/measured co-regulations) for the predictions
(Appendix Fig S3). It performed consistently better than a random
baseline (see Material and Methods) over the considered range of
correlation coefficient thresholds. We also compared the results
with network solutions obtained hiding either TFs or kinases/phos-
phatases. When TFs were hidden, COSMOS performed consistently
better than the random baseline and reached a maximum TPR of
0.62. Of note, this curve was estimated from only n = 21 co-regula-





























Figure 4. COSMOS subnetwork centered on the interferon gamma response pathway.
The figure includes the main members of the interferon gamma response pathway, the most enriched cancer hallmark in the full COSMOS network. We also display the
metabolic enzymes that were hypothesized to be influenced downstream of this pathway, such as BCAT1 and PNP. The numbered mechanisms are discussed in the
main text.
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performed again consistently better than the random baseline and
reached a maximum TPR of 0.58 (n = 228). In both cases, the
performance of COSMOS was slightly larger than the full COSMOS
performance (TPR = 0.55). This could be due to a lack of consis-
tency across the omics data, although due to the low number of
comparisons we could not make a conclusive statement. These
results suggest that COSMOS’ performance is relatively robust to
removing either the phosphoproteomics or transcriptomics layers
when trying to find connection between signaling and metabolism.
However, using the three omics layers together yielded a larger
network (367 edges (full) vs. 294 (hidden kinases) and 135 edges
(hidden TFs)) and denser (1.67 edge/node ratio vs. 1.54 and 1.19
edge/node ratio, respectively) than when one omics layer was
removed (Dataset EV3). Hence, using all layers yield a greater
number of mechanistic hypotheses, even if not necessarily of higher
quality.
To study the robustness of COSMOS to changes in the PKN, we
generated a series of partially degraded PKN by randomly shuffling
an increasing number of edges in the original PKN (2, 10, 20, 30,
40, 50% of all edges shuffled completely randomly). We ran
COSMOS with each version of the PKN. We first compared the
results of the “forward” COSMOS runs (connecting TFs and kinases
with downstream metabolites). We calculated the absolute dif-
ference between the edge weight of the results (see Materials and
Methods, meta PKN contextualization) obtained from each shuffled
PKN with the result obtained from the original PKN. The edge
weight represents the frequency of appearance (in %) of an edge
across all the networks in the pool of network solutions. This
showed that for the 2% shuffled network, the differences were rela-
tively small (median of the absolute weight difference = 10), with
4% of edges flipped (i.e., 0 weight in shuffled network and 100
weight in original network, or vice versa). As expected, the dif-
ferences were higher regarding the other shuffled networks, with
medians weight differences of 10, 14, 23, 50, 28, and 35 for the 2,
10, 20, 30, 40, and 50% shuffled PKN, respectively (Appendix Fig
S4A).
We then compared the results of the “backward” COSMOS runs
(connecting metabolites with downstream TFs and kinases). Here,
the comparison was far less quantitative because the optimization
reported only a single solution for all runs except in the case of the
20% shuffled PKN (Appendix Fig S4B). 61, 31, 18, 12, 8, and 8% of
edge weight differences were equal to 0 for the 2, 10, 20, 30, 40, and
50% shuffled PKN, respectively.
In both “forward” and “backward” runs, the network results had
a relatively similar number of edges from the original and shuffled
PKNs (min = 142, max = 342, mean = 263, SD = 63). The optimiza-
tion thus consistently excluded a common set of edges covering the
vast majority of the network, that contains over 56,000 edges.
We also compared the results we obtained from our samples
with results obtained using another independent ccRCC dataset. We
obtained the transcriptomics and phosphoproteomics dataset of the
Clinical Proteomic Tumor Analysis Consortium (CPTAC) ccRCC
patient cohort (Clark et al, 2020). Following the same approach as
with our patient samples, we performed the differential analysis
between tumor and healthy tissue for both omics datasets and esti-
mated TFs and kinase/phosphatase activities. Then, we ran
COSMOS to find mechanistic hypotheses explaining the connections
between deregulated transcription factors and kinases/
phosphatases. The resulting COSMOS network was coherent with
the results shown in the original publication and also provided addi-
tional information on the crosstalks between deregulated kinases
and transcription factors. In particular, COSMOS captured the
signaling crosstalks between EGF, VEGF, AKT, MAPK, MTOR, NFKB,
and MYC (Dataset EV4). Finally, we compared which biological
processes were captured in the COSMOS network generated from
the data of our patient samples and the COSMOS network generated
from the CPTAC ccRCC patient cohort. As shown in Fig EV3, the
top over-represented pathways were very consistent between the
two studies. Notably, PI3K-AKT-MTOR signaling and G2M check-
point (Clark et al, 2020), TNFA signaling via NFKB (Al-Lamki et al,
2010), interferon gamma response (Thapa et al, 2013), WNT beta
catenin signaling (Xu et al, 2016), and IL6 JAK STAT3 signaling
pathway were all significantly over-represented (P < 0.02).
Finally, we applied COSMOS to a public breast cancer dataset
including transcriptomics and fluxomics measurements (Katzir et al,
2019) to connect signaling directly with metabolic flux estimation,
instead of metabolite abundance measurements as done in the
previous cases. We performed a differential analysis of transcript
abundance and flux values between tumor cells cultured with and
without glutamine. We then looked for mechanistic hypotheses
connecting TF activity deregulations and changes in flux values.
Coherently with the original study, almost all metabolites of the
TCA cycle, glycolysis and pentose phosphate pathway were
predicted to be down-regulated by COSMOS (Appendix Fig S5).
Interestingly, COSMOS finds HIF1A as a master regulator of glycoly-
sis through his effect on HK1/2, GAPDH, GCK, ENO1, and LDHA
transcription. This is consistent with the known role of HIF1A in
breast cancer (Samanta et al, 2014; Masoud & Li, 2015; Zhang et al,
2015; Singh et al, 2017). The down-regulation of MYC is also in line
with the decreased activity of HK2 and LDHA and GLS1 enzymes
which are important in aerobic glycolysis and glutamine catabolism
(Dong et al, 2020).
Discussion
In this paper, we present COSMOS, an analysis pipeline to systemat-
ically generate mechanistic hypotheses by integrating multi-omics
datasets with a broad range of curated resources of interactions
between protein, transcripts, and metabolites.
We first showed how TF, kinase, and phosphatase activities
could be coherently estimated from transcriptomics and phospho-
proteomics datasets using footprint-based analysis. This is a critical
step before further mechanistic exploration. Indeed, transcript and
phosphosite usually offer limited functional insights by themselves
as their relationship with corresponding protein activity is usually
not well characterized. Yet, they can provide information on the
activity of the upstream proteins regulating their abundances. Thus,
the functional state of kinases, phosphatases, and TFs is estimated
from the observed abundance change of their known targets, i.e.,
their molecular footprint. Thanks to this approach, we could simul-
taneously characterize protein functional states in tumors at the
level of signaling pathway and transcriptional regulation. Key actors
of hypoxia response, inflammation pathway, and oncogenic genes
were found to have especially strong alteration of their functional
states, such as HIF1A, EPAS1, STAT1/2, MYC, and CDK2. Loss of
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VHL is a hallmark of ccRCC and is directly linked to the stability of
the HIF (HIF1A and EPAS1) proteins found deregulated by our anal-
ysis (Maxwell et al, 1999; Ivan et al, 2001; Jaakkola et al, 2001).
Finding these established signatures of ccRCC to be deregulated in
our analysis is a confirmation of the validity of this approach.
We then applied COSMOS with a novel meta causal Prior Knowl-
edge Network spanning signaling, transcription, and metabolism to
systematically find potential mechanisms linking deregulated
protein activities and metabolite concentrations. To the best of our
knowledge, this is the first attempt to integrate these three omics
layers together in a systematic manner using causal reasoning.
Previous methods studying signaling pathways with multi-omics
quantitative datasets (Drake et al, 2016) connected TFs with kinases
but they were limited by the preselected locally coherent subnet-
work of the TieDIE algorithm. Introducing global causality along
with metabolomics data allows us to obtain a direct mechanistic
interpretation of links between proteins at different regulatory levels
and metabolites. The goal of our approach is to find a coherent set
of such mechanisms connecting as many of the observed deregu-
lated protein activities and metabolite concentrations as possible.
Using COSMOS is particularly interesting as all the proposed mecha-
nisms between pairs of molecules (proteins and metabolites) have
to be plausible not only in the context of their own pairwise interac-
tion but also with respect to all other molecules that we wish to
include in the model. For example, the proposed activation of MYC
by NFKB1 and MAPK1 is further supported by STAT3 activation,
because MAPK1 is also known to activate STAT3. Thus, we devel-
oped COSMOS to scale this type of reasoning up to the entire PKN
with all significantly deregulated protein activities and metabolites.
We relied on an ILP optimization through the CARNIVAL R package
(Liu et al, 2019b) to contextualize this PKN with our data. We
refined the optimization procedure to handle this very large PKN
and built an R package to facilitate others to use it with their own
data. Given a set of deregulated TFs, kinases/phosphatases, or
metabolites, COSMOS provides the users with a set of coherent
mechanistic hypotheses to explain changes observed in a given
omics layer with upstream regulators from other omics layers. Thus,
its aim is to integrate measured data with prior knowledge in a
consistent and systematic manner, not to explicitly predict the
outcome of new experiments.
Since the interferon gamma response pathway was the most
over-represented cancer hallmark in the COSMOS network solution,
we investigated further the relevance of the mechanistic hypothesis
connecting members of this pathway. The network showed that the
crosstalks between MAPK1, NFKB1, MYC, HIF1A, and YY1 could
explain the deregulation in glutamine and reduced glutathione meta-
bolism, as well as inosine, hypoxanthine, and adenine. These were
particularly relevant as they were important interactions in ccRCC.
MYC and glutamine metabolism appear to be an interesting thera-
peutic target of ccRCC (Shroff et al, 2015). YY1 is a known indirect
inhibitor of MYC involved in cancer development (Austen et al,
1998). The COSMOS network showed YY1 could also potentially
have a role in the down-regulation of the ADA and PNP metabolic
enzyme activities. Coherently, PNP has been shown to be non-
essential in ccRCC cell lines, which is expected from down-regulated
metabolic enzymes (Gatto et al, 2015). In addition, the link shown
by COSMOS between NFKB1 and MYC can have implications for the
treatment of ccRCC, due to its pivotal role in arsenite (a drug used
in chemotherapy) treatment of cancer (Huang et al, 2014). Further-
more, the activation of the NFKB1-MYC link in FBW7-deficient cells
seems to sensitize them to Sorafinib (a MEK-Raf inhibitor), a drug
used in treatment of primary kidney cancer (Huang et al, 2014). In
addition, NFKB1 and MYC are both promising ccRCC treatment
targets (Peri et al, 2013; Bailey et al, 2017). The link shown by
COSMOS between KMT2A and adenosine is interesting, because
KMT2A mutations have been reported in a number of ccRCC
patients (Yan et al, 2019), suggesting that this enzyme might play a
functional role in ccRCC development. Moreover, it has been
proposed, at least in vitro, that ccRCC cell lines with low basal
levels of phospho-AKT were sensitive to treatment with an adeno-
sine analog (Kearney et al, 2015). The link between YES1, MAPK1,
and SMAD4 in the COSMOS network is especially relevant consider-
ing that YES1 is a known targetable oncogene (Hamanaka et al,
2019). These examples illustrate the ability of COSMOS to extract
mechanistic hypotheses to understand and potentially improve
treatment of cancer by integration of multiple omics data and prior
knowledge.
However, it is important to mention that COSMOS is only aimed
at providing hypotheses to further explore experimentally. COSMOS
does not aim at recapitulating all the molecular interactions that
may be happening in a given context. Currently, COSMOS simply
provides a large set of coherent mechanistic hypotheses, given the
data and prior knowledge available. We argue that this facilitates
the interpretation of a complex multi-omics dataset and guides the
exploration of biological questions.
We assessed the performances and robustness of our approach.
We computed a tumor specific correlation network of TF and kinase
activities and compared it to the co-regulation predicted by
COSMOS. This yielded encouraging results, though imperfect,
underscoring the fact that the mechanisms proposed by COSMOS—
like those by any similar tool—are hypotheses. It also highlighted
that adding more omics data to integrate allows to generate more
hypotheses and connect them together, but does not necessarily
improve their predictive performances.
There are three main known limits to the predictions of
COSMOS. First, the input data are incomplete. Only a limited frac-
tion of all potential phosphosites and metabolites are detected by
mass spectrometry. This means that we have no information on a
significant part of the PKN; part of the unmeasured network is kept
in the analyses and the values are estimated as intermediate
“hidden values”. Second, not all regulatory events between TFs,
kinase, and phosphatases and their targets are known, and activity
estimation is based only on the known regulatory relationships.
Thus, many TFs, kinase, and phosphatases are not included
because they have no curated regulatory interactions or no detected
substrates in the data. Third, and conversely, COSMOS will find
putative explanations within the existing prior knowledge that may
not be the true mechanism.
These problems mainly originate from the importance that is
given to prior knowledge in this method. Since prior knowledge is
by essence incomplete, the next steps of improvement could
consist of finding ways to extract more knowledge from the
observed data to weight in the contribution of prior knowledge.
For instance, one could use the correlations between transcripts,
phosphosites and metabolites to quantify the interactions available
in databases such as OmniPath. Importantly, any other omics that
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relate to active molecules (such as miRNAs or metabolic enzyme
fluxes) can be used to estimate protein activities through footprint
approaches (such as DNA accessibility or PTMs other than phos-
phorylation) can be seamlessly integrated (as we showed with the
fluxomic of the breast cancer dataset). Moreover, COSMOS was
designed to work with bulk omics datasets, and it will be very
exciting to find ways of applying this approach to single cell data-
sets. Encouragingly, the footprint methods that bring data into
COSMOS seem fairly robust to the characteristics of single-cell
RNA data such as dropouts (Holland et al, 2020). Related to the
importance of prior knowledge, the PKN can also depend on how
we interpret the information we have about molecular interactions.
In particular, we converted the reaction network of Recon3D into a
causal network where metabolite reactants “activate” metabolic
enzymes, and metabolic enzymes “activate” metabolite products.
This first approximation assumes that metabolite abundances are
only driven by their production rates. We plan to refine this in the
future to include that metabolite abundances can change as a
result of consumption as well. Finally, we expect that in the future,
data generation technologies will increase coverage and our prior
knowledge will become more complete, reducing the mentioned
limitations. In the meantime, we believe that COSMOS is already a
useful tool to extract causal mechanistic insights from multi-omics
studies.
Materials and Methods
Reagents and Tools table
Reagent/Resource Reference or Source Identifier or Catalog Number
Chemicals, enzymes, and other reagents
Guanidine hydrochloride Sigma-Aldrich G3272
Ammonium carbonate Merck 1.59504.0250
Ammonium hydroxide Acros Organics 255210010
OptimaTM LC/MS grade water Fisher Scientific W6-4
OptimaTM LC/MS grade acetonitrile Fisher Scientific A955-4
SeQuant ZIC-pHILIC analytical column (150 × 2.1 mm, 5 lm) Merck 1.50460.0001
SeQuant ZIC-pHILIC guard (20 × 2.1 mm, 5 lm) Merck 1.50438.0001
Complete mini EDTA-free protease inhibitor cocktail Roche 04693124001
1.4 mm zirconium oxide beads Bertin Technologies KT03961-1-103.BK
2.8 mm zirconium oxide beads Bertin Technologies KT03961-1-102.BK
Tris(2-carboxyethyl)phosphine Sigma-Aldrich C4706
Chloroacetamide Sigma-Aldrich 22790
Lys-C Wako Chemicals 129-02541
Trizma base Sigma-Aldrich T1503
Trypsin Sigma-Aldrich T6567
C18 Sep-Pak Cartridges Waters WAT054955
TMT10plex isobaric label reagent set Thermo Fischer Scientific 90406
TMT11-131C Label Reagent Thermo Fischer Scientific A34807
5 lm Titansphere GL Sciences GS 502075000
2,5-dihydroxybenzoic acid Sigma-Aldrich 85707
Empore C8 SPE Disks, 47mm Empore 66882-U
Ammonia solution 25% Merck 1054321011
Ammonium bicarbonate Sigma-Aldrich 09830
Acetonitrile Merck 1.00030.2500
Formic Acid Merck 1.00264.1000
Trifluoro acetic acid Sigma-Aldrich 8.08260.0501
1.9 lm Reprosil-Pur 120 C18 beads Dr. Maisch R119.aq.0003
75 lm ID capillary material CM Scientific TSP075375
Guanidine hydrochloride Sigma-Aldrich G3272
Complete mini EDTA-free protease inhibitor cocktail Roche 04693124001
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Reagents and Tools table (continued)
Reagent/Resource Reference or Source Identifier or Catalog Number
1.4 mm zirconium oxide beads Bertin Technologies KT03961-1-103.BK
2.8 mm zirconium oxide beads Bertin Technologies KT03961-1-102.BK
Tris(2-carboxyethyl)phosphine Sigma-Aldrich C4706
Chloroacetamide Sigma-Aldrich 22790
Lys-C Wako Chemicals 129-02541
Trizma base Sigma-Aldrich T1503
Trypsin Sigma-Aldrich T6567
C18 Sep-Pak Cartridges Waters WAT054955
TMT10plex isobaric label reagent set Thermo Fischer Scientific 90406
TMT11-131C Label Reagent Thermo Fischer Scientific A34807
5 lm Titansphere GL Sciences GS 502075000
2,5-dihydroxybenzoic acid Sigma-Aldrich 85707
Empore C8 SPE Disks, 47mm Empore 66882-U
Ammonia solution 25% Merck 1054321011
Ammonium bicarbonate Sigma-Aldrich 09830
Acetonitrile Merck 1.00030.2500
Formic Acid Merck 1.00264.1000
Trifluoro acetic acid Sigma-Aldrich 8.08260.0501
1.9 lm Reprosil-Pur 120 C18 beads Dr. Maisch R119.aq.0003
75 lm ID capillary material CM Scientific TSP075375
RNAeasyMini Kit Qiagen 74106
KAPA RNA Hyperprep Kit Roche KR1351
Software
MaxQuant 1.6.0.17 https://maxquant.net/
Xcalibur QuanBrowser and QualBrowser (version 3.1) Thermo Fisher Scientific
R (version 4.0.2) R Core Team (2020)
CPLEX Optimizer (version 12.7.1.0) IBM corp
Other
Denator Stabilizor T1 Denator
Precellys 24 lysis & homogenization Bertin Technologies
Sonics Vibra-Cell Sonicator Sonics & Materials
SpeedVac Concentrator Plus Eppendorf
Nanodrop 2000 Spectrophotometer Thermo Fischer Scientific
Reversed-phase Acquity CSH C18 1.7 lm 1 × 150 mm column Waters
UltiMate 3000 high-pressure liquid chromatography (HPLC) system Dionex
Q Exactive HF-X Thermo Fischer Scientific
EASY-nLC 1200 UHPLC system Thermo Fischer Scientific
Denator Stabilizor T1 Denator
NovaSeq Illumina
Precellys 24 lysis & homogenization Bertin Technologies
Sonics Vibra-Cell Sonicator Sonics & Materials
SpeedVac Concentrator Plus Eppendorf
Nanodrop 2000 Spectrophotometer Thermo Fischer Scientific
Reversed-phase Acquity CSH C18 1.7 lm 1 × 150 mm column Waters
UltiMate 3000 high-pressure liquid chromatography (HPLC) system Dionex
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Reagents and Tools table (continued)
Reagent/Resource Reference or Source Identifier or Catalog Number
Q Exactive HF-X Thermo Fischer Scientific
EASY-nLC 1200 UHPLC system Thermo Fischer Scientific
Methods and Protocols
Sample collection and processing
We included a total of 22 samples from 11 renal cancer patients (6
men, age 65.0  14.31, 5 women, age 65.2  9.257 (mean  SD))
for transcriptomics. Phosphoproteomics was also measured in a
subset of 18 samples from 9 of these patients (6 men, age
65  14.31; 3 women, age 63.33  11.06 (mean  SD)), and meta-
bolomics was also measured in 16 samples from 8 out of these 9
patient (5 men, age 62  13.23; 3 women, age 63.33  9.89
(mean  SD), Fig EV4, Dataset EV1). Patients underwent nephrec-
tomy due to renal cancer. We processed tissue from within the
cancer and a distant unaffected area of the same kidney. The tissue
was snap-frozen immediately after nephrectomy within the opera-
tion room. The clinical data of the included patients is outlined in
Dataset EV1. Histological evaluation showed clear renal cell carci-
noma in all patients.
Ethics
The local ethics committee of the University Hospital RWTH Aachen
approved all human tissue protocols for this study (EK-016/17). The
study was performed according to the declaration of Helsinki.
Kidney tissues were collected from the Urology Department of the
University Hospital Eschweiler from patients undergoing partial/- or
nephrectomy due to kidney cancer. All patients gave informed
consent.
Human tissue processing
Kidney tissues were sampled by the surgeon from normal and tumor
regions. The tissue was snap-frozen on dry-ice or placed in
prechilled University of Wisconsin solution (#BTLBUW, Bridge to
Life Ltd., Columbia, U.S.) and transported to our laboratory on ice.
RNA Isolation, library preparation, NGS sequencing
RNA was extracted according to the manufacturer ́s instructions
using the RNeasy Mini Kit (QIAGEN). For rRNA-depleted RNA-seq
using 1 and 10 ng of diluted total RNA, sequencing libraries were
prepared with KAPA RNA HyperPrep Kit with RiboErase (Kapa
Biosystems) according to the manufacturer’s protocol. Sequencing
libraries were quantified using quantitative PCR (New England
Biolabs, Ipswich, USA). Equimolar pooling of the libraries was
normalized to 1,4 nM, denatured using 0.2 N NaOH and neutralized
with 400 nM Tris pH 8.0 prior to sequencing. Final sequencing was
performed on a Novaseq6000 platform (IIlumina) according to the
manufacturer’s protocols (Illumina, CA, USA).
Metabolomics
Snap-frozen tissue specimens were cut and weighed into Precellys
tubes prefilled with ceramic beads (Stretton Scientific Ltd., Derby-
shire, UK). An exact volume of extraction solution (30% acetoni-
trile, 50% methanol, and 20% water) was added to obtain 40 mg
specimen per mL of extraction solution. Tissue samples were lysed
using a Precellys 24 homogenizer (Stretton Scientific Ltd., Derby-
shire, UK). The suspension was mixed and incubated for 15 min at
4°C in a Thermomixer (Eppendorf, Germany), followed by centrifu-
gation (16,000 g, 15 min at 4°C). The supernatant was collected and
transferred into autosampler glass vials, which were stored at
80°C until further analysis.
Samples were randomized to avoid bias due to machine drift
and processed blindly. LC-MS analysis was performed using a Q
Exactive mass spectrometer coupled to a Dionex U3000 UHPLC
system (both Thermo Fisher Scientific). The liquid chromatogra-
phy system was fitted with a Sequant ZIC-pHILIC column
(150 mm × 2.1 mm) and guard column (20 mm × 2.1 mm) from
Merck Millipore (Germany) and temperature maintained at 45
°C. The mobile phase was composed of 20 mM ammonium
carbonate and 0.1% ammonium hydroxide in water (solvent A),
and acetonitrile (solvent B). The flow rate was set at 200 µL/
min with the gradient described previously (Mackay et al, 2015).
The mass spectrometer was operated in full MS and polarity
switching mode. The acquired spectra were analyzed using XCal-
ibur Qual Browser and XCalibur Quan Browser software
(Thermo Scientific).
Phosphoproteomics
Snap-frozen tissues were heat inactivated (Denator T1 Heat Stabili-
zor, Denator) and transferred to a GndCl solution (6 M GndCl,
25 mM Tris, pH 8.5, Roche Complete Protease Inhibitor tablets
(Roche)) and homogenized by ceramic beads using 2 steps of 20 s
at 5,500 rpm (Precellys 24, Bertin Technologies). The tissues were
heated for 10 min at 95°C followed by micro tip sonication on ice
and clarified by centrifugation (20 min, 16,000 g, 4°C). Samples
were reduced and alkylated by adding 5 mM tris(2-carboxyethyl)
phosphine and 10 mM chloroacetamide for 20 min at room temper-
ature.
Lysates were digested by Lys-C (Wako) in an enzyme/protein
ratio of 1:100 (w/w) for 1 h, followed by a dilution with 25 mM tris
buffer (pH 8.5), to 2 M guanidine-HCl and further digested over-
night with trypsin (Sigma-Aldrich; 1:100, w/w). Protease activity
was quenched by acidification with TFA, and the resulting peptide
mixture was concentrated on C18 Sep-Pak Cartridges (Waters).
Peptides were eluted with 40% ACN followed by 60% ACN. The
combined eluate was reduced by SpeedVac, and the final peptide
concentration was estimated by measuring absorbance at A280 on a
NanoDrop (Thermo Fisher Scientific). Peptide (300 lg) from each
sample was labeled with 1 of 11 different TMT reagents according
to the manufacturer’s protocol (Thermo Fisher Scientific) for a total
of four TMT sets. Each set comprised 10 samples and a common
internal reference (composed of equal amounts of digested material
from all samples).
After labeling, the samples were mixed and phosphopeptides
were further enriched using titanium dioxide beads (5 lm
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Titansphere, GL Sciences, Japan). TiO2 beads were pre-incubated in
2,5-dihydroxybenzoic acid (20 mg/ml) in 80% ACN and 1% TFA
(5 ll/mg of beads) for 20 min. Samples were brought to 80% ACN
and 5% TFA. 1.5 mg beads (in 5 ll of DHB solution) were added to
each sample, which was then incubated for 20 min while rotating.
After incubation, the beads were pelleted and fresh TiO2 beads were
added to the supernatant for a second enrichment step. Beads were
washed with five different buffers: (i) 80% ACN and 6% TFA, (ii)
10% ACN and 6% TFA, (iii) 80% ACN and 1% TFA, (iv) 50% ACN
and 1% TFA, (v) 10% ACN and 1% TFA. The final washing step
was performed on a C8 stage tip, from which the phosphopeptides
were with 20 ll 5% NH4OH followed by 20 ll 10% NH4OH with
25% ACN. Eluted peptides were fractionated using a reversed-phase
Acquity CSH C18 1.7 lm 1 × 150 mm column (Waters, Milford,
MA) on an UltiMate 3000 high-pressure liquid chromatography
(HPLC) system (Dionex, Sunnyvale, CA) operating at 30 ll/min.
Buffer A (5 mM ammonium bicarbonate) and buffer B (100% ACN)
were used. Peptides were separated by a linear gradient from 5% B
to 35% B in 55 min, followed by a linear increase to 70% B in
8 min and 12 fractions were collected in a concatenated manner.
The peptide solution was adjusted in volume to an appropriate
concentration and kept in loading buffer (5% ACN and 0.1% TFA)
prior to autosampling. An in-house packed 15 cm, 75 lm ID capil-
lary column with 1.9 lm Reprosil-Pur C18 beads (Dr. Maisch,
Ammerbuch, Germany) was used with an EASY-nLC 1200 system
(Thermo Fisher Scientific, San Jose, CA). The column temperature
was maintained at 40°C using an integrated column oven (PRSO-V1,
Sonation, Biberach, Germany) and interfaced online with a Q Exac-
tive HF-X mass spectrometer. Formic acid (FA) 0.1% was used to
buffer the pH in the two running buffers used. The gradients went
from 8 to 24% acetonitrile (ACN) in 50 min, followed by 24–36% in
10 min. This was followed by a washout by a 1/2 min increase to
64% ACN, which was kept for 4.5 min. Flow rate was kept at 250
nL/min. Re-equilibration was done in parallel with sample pickup
and prior to loading with a minimum requirement of 0.5 ll of 0.1%
FA buffer at a pressure of 600 bar.
The mass spectrometer was running in data-dependent acquisi-
tion mode with the spray voltage set to 2 kV, funnel RF level at 40,
and heated capillary at 275°C. Full MS resolutions were set to
60,000 at m/z 200 and full MS AGC target was 3E6 with an IT of
25 ms. Mass range was set to 375–1500. AGC target value for frag-
ment spectra was set at 1E5, and intensity threshold was kept at
2E5. Isolation width was set at 0.8 m/z and a fixed first mass of
100 m/z was used. Normalized collision energy was set at 33%.
Peptide match was set to off, and isotope exclusion was on.
Raw MS files were analyzed by MaxQuant software version
1.6.0.17 using the Andromeda search engine. Proteins were identi-
fied by searching the higher-energy collisional dissociation (HCD)–
MS/MS peak lists against a target/decoy version of the human
UniProt protein database (release April 2017) using default settings.
Carbamidomethylation of cysteine was specified as fixed modifi-
cation, and protein N-terminal acetylation, oxidation of methionine,
pyro-glutamate formation from glutamine, and phosphorylation of
serine, threonine, and tyrosine residues were considered as variable
modifications. The “maximum peptide mass” was set to 7,500 Da,
and the “modified peptide minimum score” and “modified maxi-
mum peptide score” were set to 25. Everything else was set to
default values. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE part-
ner repository. Data are available via ProteomeXchange with identi-
fier PXD018218 with the following reviewer account details:
Username: reviewer81921@ebi.ac.uk Password: Kidney2020.
Data normalization and differential analysis
In the phosphoproteomics dataset, 19285 unique phosphosites were
detected across 18 samples. Visual inspection of the raw data PCA
first 2 components indicated two major batches of samples (1st
batch : "38KI", "38TU", "15KI", "15TU", "29KI", "29TU", "16KI",
"16TU", "32KI", "32TU", "35KI", "35TU"; 2nd batch : "40KI",
"40TU", "24KI", "24TU", "11KI", "11TU"). Thus, each batch was
first normalized using the VSN R package (Huber et al, 2002;
V€alikangas et al, 2018). We removed p-sites that were detected in
< 4 samples, leaving 14,243 unique p-site to analyze. Visual inspec-
tion of the PCA first two components of the normalized data
revealed that the first batch of samples could itself be separated in 3
batches (4 batches across all samples). Thus, we used the remove-
BatchEffect function of LIMMA to remove the linear effect of the 4
batches. Differential analysis was performed using the standard
sequence of lmFit, contrasts.fit and eBayes functions of LIMMA,
with FDR correction.
For the transcriptomics data, counts were extracted from fast.q
files using the RsubRead R package and GRCh37 (hg19) reference
genome. Technical replicates were averaged, and genes with aver-
age counts under 50 across samples were excluded, leaving 15919
genes measured across 22 samples. To allow for logarithmic trans-
formation, 0 count values were scaled up to 0.5 (similar to the voom
function of LIMMA). Counts were then normalized using the VSN R
package function and differential analysis was performed with
LIMMA package, in the same way as the phosphoproteomics data.
For the metabolomics data, 107 metabolites were detected in 16
samples. Intensities were normalized using the VSN package. Dif-
ferential analysis was done using LIMMA in the same manner as for
phosphoproteomics and transcriptomics. All data are available at:
https://github.com/saezlab/COSMOS.
Footprint-based analysis
TF-target collection was obtained from DoRothEA A,B,C and D
interaction confidence levels from the DoRothEA R package (version
1.1.0). For the enrichment analysis, the viper algorithm (Alvarez
et al, 2016) was used with the LIMMA moderated t-value as gene
level statistic (Zyla et al, 2017). The eset.filter parameter was set to
FALSE. Only TFs with at least 25 measured transcripts were
included.
Kinase substrate collection was obtained using the default
resource collection of OmniPath, with the URL “http://omnipathdb.
org/ptms?fields=sources,references&genesymbols=1” (version of
2020 Feb 05). For the enrichment analysis, the viper algorithm was
used with the LIMMA moderated t-value as phosphosite level statis-
tic. The eset.filter parameter was set to FALSE. Only TFs with at
least 5 measured transcripts were included. All data are available at
https://github.com/saezlab/COSMOS_MSB/tree/main/data.
Meta PKN construction
To propose mechanistic hypotheses spanning through signaling,
transcription and metabolic reaction networks, multiple types of
interactions have to be combined together in a single network.
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Thus, we built a meta Prior Knowledge Network (PKN) from
three online resources, to incorporate three main types of interac-
tions. The three types of interactions are protein–protein interac-
tions, metabolite-protein allosteric interactions, and metabolite-
protein interactions in the context of a metabolic reaction
network. Protein–protein interaction was imported from OmniPath
with the URL http://omnipathdb.org/interactions?types=post_tra
nslational,transcriptional&datasets=omnipath,pathwayextra,
dorothea&fields=sources,references,curation_effort,dorothea_leve
l,type&genesymbols=yes (version of 2020 July 17), and only
signed directed interactions were included (is_stimulation or is_in-
hibition columns equal to 1). Metabolic-protein allosteric interac-
tions were imported from the STITCH database (version of 2019
November 06), with combined confidence score ≥ 900 after exclu-
sion of interactions relying mainly on text mining.
For metabolic-protein interactions in the context of metabolic
reaction network, Recon3D was downloaded from https://www.
vmh.life/#downloadview (version of 2019 Feb 19). Then, the gene
rules (“AND” and “OR”) of the metabolic reaction network were
used to associate reactants and products with the corresponding
enzymes of each reaction. When multiple enzymes were associated
with a reaction with an “AND” rule, they were combined together
as a single entity representing an enzymatic complex. Then, reac-
tants were connected to corresponding enzymatic complexes or
enzymes by writing them as rows of simple interaction format
(SIF) table of the following form: reactant;1;enzyme. In a similar
manner, products were connected to corresponding enzymatic
complexes or enzymes by writing them as rows of simple interac-
tion format (SIF) table of the following form: enzyme;1;product.
Thus, each row of the SIF table represents either an activation of
the enzyme by the reactant (i.e., the necessity of the presence of
the reactant for the enzyme to catalyze it’s reaction) or an activa-
tion of the product by an enzyme (i.e., the product presence is
dependent on the activity of its corresponding enzyme). Most
metabolite–protein interactions in metabolic reaction networks are
not exclusive, thus measures have to be taken in order to preserve
the coherence of the reaction network when converted to the SIF
format. First, metabolites that are identified as “Coenzymes” in the
Medical Subject Heading Classification (as referenced in the
PubChem online database) were excluded. Then, we looked at the
number of connections of each metabolite and searched the mini-
mum interaction number threshold that would avoid excluding
main central carbon metabolites. Glutamic acid has 338 interac-
tions in our Recon3D SIF network and is the most connected
central carbon metabolite, thus any metabolites that had more than
338 interactions was excluded. An extensive list of Recon3D
metabolites (PubChem CID) with their corresponding number of
connections is available in Dataset EV2. Metabolic enzymes
catalyzing multiple reactions were uniquely identified for each
reaction to avoid cross-links between reactants and products of dif-
ferent reactions. Finally, exchange reactions were further uniquely
identified according to the relevant exchanged metabolites, as to
avoid confusion between transformation of metabolites and simply
exchanging them between compartments.
Finally, each network (protein–protein, allosteric metabolite–
protein, and reaction network metabolite–protein) was combined
into a single SIF table. This network is available in the COSMOS
R package.
Meta PKN contextualization
COSMOS uses the CARNIVAL R package to perform the network opti-
mization via an ILP algorithm. In brief, we try to minimize the value
of an objective function that depends on two main factors: (i) the
mismatch between the simulated values of kinases, TFs, and metabo-
lites for a given causal network and the corresponding available
values estimated from the measurements and (ii) the size of the solu-
tion network. For each run, given the prior knowledge network and
the input and measurements, a set of constraints are generated to
define the solution space (based on the objective function) that the
ILP solver (IBM CPLEX in our study) explores to find an optimal solu-
tion (Melas et al, 2015; preprint: Liu et al, 2019a). After a given
amount of time (decided by the user), the search is stopped and the
best solution at this point is returned by CPLEX. The solution is typi-
cally a pool (or family) of networks that are all equally optimal with
respect to the objective function. Thus, CARNIVAL reports the solu-
tion as a set of edges with an associated weight that represent their
frequency of appearance in the current network pool. CARNIVAL
needs a set of starting and end nodes to look for paths in between.
TFs, kinases, and phosphatases absolute normalized enrichment
scores greater than 1.7 standard deviation were considered deregu-
lated. Coherently, metabolites with uncorrected P-values smaller than
0.05 were considered deregulated. We give more information on the
rational to choose an appropriate threshold in the Appendix Note 1.
This yielded a set of 98 TFs, 25 kinases/phosphatase, and 41 metabo-
lites to be used as input and measurements for COSMOS.
Then, the PKN is pre-processed in three steps to make it easier
for CARNIVAL to find a solution network, as detailed below.
Filtering
The generic meta PKN contained 117,065 edges. We first filtered the
meta PKN to keep only genes that are expressed. With the main
dataset presented in this paper, we considered the 15,919 genes that
remained after removing the lowly expressed genes (defined as those
with average count under 50 across the 22 samples, based on the
count distribution) as expressed. This reduced the size of the meta
PKN from 117,065 edges to 66,749 edges.
Reduction
At this stage, the meta PKN may contain independent network
modules that do not include any of the actual input nodes (the signifi-
cant TF, kinase/phosphatase activities, and metabolites). Thus, we fil-
ter out any gene that cannot be connected to any input node. We
define a maximum given number of steps to avoid excessively long
causal paths that would be un-plausible and thus have unclear biolog-
ical relevance. We chose 8 steps downstream of signaling inputs for
the “forward” run (signaling to metabolism) and 7 steps downstream
of metabolic inputs for the “backward” run (metabolism to signaling)
as > 90% of the PKN could be captured in that number of steps.
Correction
We use the transcriptomics data differential gene expression analy-
sis results to directly remove any edge that leads to an incoherence
between a TF activity and its target transcript abundance change
(which is a wrongly predicted transcriptional regulation event). This
is done once before running CARNIVAL, using TF activities
predicted with DoRothEA. Then, we do a pre-run of CARNIVAL
(TFs/kinases/phosphatases -> metabolites) to generate a first
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solution network. We can subsequently use TF activities predicted
by CARNIVAL to filter out any wrongly predicted transcriptional
regulation event from the meta PKN (Appendix Fig S3A).
Then, we first set the deregulated kinases, phosphatases, and
TFs as starting points and deregulated metabolites as end points
(“forward” run). This direction represents regulations first going
through the signaling and transcriptional part of the cellular
network and stops at deregulated metabolites in the metabolic reac-
tion network. However, since metabolite concentration can also
influence the activity of kinases and TFs through allosteric regula-
tions, we also ran CARNIVAL by setting deregulated metabolites as
starting points and deregulated TFs, kinases, and phosphatases as
end points (“backward” run). The “forward” run was performed
with a time limit of 7,200 s and yielded a network of 162 edges. The
“backward” run was performed with a time limit of 21,800 s and
yielded a network of 302 edges.
There was a single incoherence in the predicted sign of ARNT2
transcription factor (1 in “forward” run, 1 in “backward” run)
between the common part of the two resulting networks. We made
the union of the two networks, resulting in a combined network of
449 unique edges, while preserving the incoherent sign of ARNT2 in
the corresponding node attributes of the network (Dataset EV5).
Coherence between COSMOS mechanistic hypotheses and
omics measurements
To assess the robustness of COSMOS predictions, we compared co-
regulations predicted by the COSMOS solution network with co-regu-
lations estimated from correlation between kinase, phosphatase, and
TF activities. When multiple nodes are co-regulated by a common
parent node in the COSMOS network, we can assume that the activ-
ity of the co-regulated nodes should be correlated. Thus, we created
a correlation network with the TF and kinase/phosphatase activities
estimated at a single sample level. To estimate the single sample
level activities, normalized RNA counts and phosphosite intensities
were scaled (minus mean over standard deviation) across samples.
Thus, the value of each gene and phosphosite is now a z-score rela-
tive to an empirical distribution generated from the measurements
across all samples. We used these z-scores as input for the viper
algorithm to estimate kinase/phosphatases and TF activities at single
sample level. Thus, the resulting activity scores in a sample are rela-
tive to all the other samples. Then, a correlation network was built
using only tumor samples. Thus, the correlation calculated this way
represents co-regulations that are supported by the available data in
tumor. We defined the ground truth for co-regulations as over a
range of absolute correlation coefficients between 0 and 1 with a
0.01 step. Thus, a True Positive here is a co-regulation predicted
from the topology of the COSMOS network that also has a corre-
sponding absolute correlation coefficient in tumor samples above the
given threshold. Since defining a ground truth in such a manner can
yield many false positives (a correlation can often be spurious), the
TPR of COSMOS was always compared to a random baseline. This
approach was repeated for COSMOS solution networks obtained
after hiding either kinase and phosphatases or TFs.
Robustness analysis
We generated a series of subsets of the original meta PKN where
increasing amounts of interactions are shuffled randomly. Starting
from the full meta PKN, we shuffled 2, 10, 20, 30, 40, and 50% of
interactions. Each shuffling is independent from the others (the
missing interactions are all selected randomly at each percentage
case). Then, COSMOS was run for each meta PKN subset with the
same parameter as the original run.
CPTAC ccRCC data analysis
The CPTAC ccRCC transcriptomics and phosphoproteomics datasets
of the proteogenomics study of ccRCC (Clark et al, 2020) were
obtained from the CPTAC data portal. We kept 20,284 phosphosites
that were detected across at least 10% of the 185 patient and
healthy samples (110 and 75, respectively).
We filtered out lowly expressed genes (RPKM (Reads Per Kilobase
of transcript, per Million mapped reads) < 170, based on the inflexion
point observed in the RPKM distribution) from the transcriptomics
dataset, keeping 14,921 genes for further analysis.
LIMMA was used for both phosphoproteomics and transcrip-
tomics to perform a differential analysis between healthy and
tumor samples.
Kinase and transcription factor activities were performed with the
same parameters as with our own ccRCC patient samples (see foot-
print-based analysis). 57 kinases and 97 TFs with absolute NES > 1.7
were used as input and measurements in the COSMOS pipeline. The
meta PKN was reduced to keep only nodes with a maximum distance
of 8 steps downstream of input kinases and TFs. The kinase to TF
CARNIVAL run was performed with a time limit of 7,200 s. The TF
to kinase run was performed with a time limit of 21,800 s. The union
of the “forward” and “backward” run networks resulted in a final
COSMOS network of 480 edges.
Breast cancer data analysis
Multi-omics experimental data for breast cancer cell lines was
obtained from (Katzir et al, 2019). The authors performed experi-
mental measurements on the MCF7 cell line under normal growth
conditions, glutamine deprivation, and oligomycin supplementation.
We obtained mRNA expression quantification of 1,905 metabolic
genes and filtered those whose mean across all conditions was at
least 0.1% of the maximum observed expression value. The experi-
ments were split in 2 batches, leading us to regress this effect out.
We then fit a linear model using the LIMMA package, from which
we obtained t-statistic values at the gene level for a given compar-
ison pair. Finally, TF activity scores were estimated using regulon
confidence A, B, and C with a minimum of 25 targets per TF with
the VIPER package, using the pleiotropy correction.
Fluxomics measurements estimated from 13C-assisted metabolo-
mics were available for 44 metabolic reactions included in the Recon
3D genome-scale metabolic model. We computed the log2 fold
change between each pair of conditions to be analyzed.
COSMOS was then used to generate context-specific sub-
networks using the transcription factor NES and the fluxomics log2
fold change as inputs and measurements. It was run without using
the correction and reduction step, with a time limit of 7,200 s on the
“forward” and “backward” runs.
Data availability
All code used in this study is available at: https://github.com/sae
zlab/COSMOS_MSB.
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• The COSMOS R package is available at: https://github.com/sae
zlab/COSMOS.
• Processed data used in this study is available at: https://github.c
om/saezlab/COSMOS_MSB/tree/master/data.
• RNA-seq counts are available: https://github.com/saezlab/
COSMOS_MSB/blob/main/data/RNA_transcriptomic_raw.csv.
• Phosphoproteomics raw data is available via ProteomeXchange
with identifier PXD018218.
• Metabolomic data is available at: : https://github.com/saezlab/
COSMOS_MSB/tree/main/data/original_metab_data.
• The meta PKN used in this study is available via the COSMOS R
package (https://github.com/saezlab/COSMOS).
Expanded View for this article is available online.
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